Alkylglycoside Surfactants for Protein Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein-based therapeutics face challenges with aggregation, leading to reduced stability, increased immunogenicity, and altered pharmacokinetics, which affect their efficacy and safety, particularly during manufacturing, storage, and delivery.
Innovation Solution
Incorporating alkylglycosides or saccharide alkyl ester surfactants into protein formulations to stabilize peptides or proteins, reduce aggregation, and minimize immunogenicity, thereby enhancing stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high concentration protein solutions are used to improve dosage efficiency, then productivity is improved, but aggregation increases leading to reduced stability and increased immunogenicity
Solution Approach 1:
The patent introduces alkylglycoside surfactants as intermediary substances that mediate between the protein and the formulation environment. These surfactants bind to hydrophobic regions of proteins, creating a protective interface that prevents protein-protein aggregation while allowing high concentration formulations to maintain stability and reduce immunogenicity.
Solution Approach 2:
The patent changes the chemical parameters of the protein formulation by adding alkylglycoside surfactants at specific concentrations (at least somewhat higher than critical micelle concentration). This parameter change modifies the formulation's physical-chemical properties to prevent aggregation while maintaining high protein concentration, thereby resolving the contradiction between productivity and stability.
2Productivity
If concentration processes are used to improve manufacturing efficiency, then productivity is improved, but aggregation increases leading to reduced stability
Solution Approach 1:
The patent applies preliminary action by adding alkylglycoside surfactants to the protein solution before concentration processes (such as ultrafiltration or chromatography). This preliminary addition ensures that the surfactant is already in place to prevent aggregation during the concentration steps, allowing efficient manufacturing without compromising protein stability.
Solution Approach 2:
The alkylglycoside surfactant acts as an intermediary protective agent throughout the concentration process, binding to hydrophobic regions and preventing protein-protein interactions that would lead to aggregation. This enables efficient concentration operations while maintaining protein stability.
3Productivity
If piston pumps are used during fill-and-finish operations to improve processing speed, then productivity is improved, but mechanical stress causes denaturation and aggregation
Solution Approach 1:
The patent applies beforehand cushioning by pre-saturating the protein solution with alkylglycoside surfactants before the solution enters the piston pump system. This prior cushioning creates a protective layer around hydrophobic regions, cushioning against the mechanical stress and shear forces generated during pump operation, thereby preventing denaturation and aggregation while allowing high-speed processing.
4Stability of the object's composition
If cold chain storage is implemented to prevent aggregation, then stability is improved, but storage and transport costs increase
Solution Approach 1:
The patent substitutes the mechanical/physical cold chain storage system with a chemical stabilization approach using alkylglycoside surfactants. These surfactants chemically bind to hydrophobic regions of proteins, providing thermal and aggregation stability that replaces the need for continuous refrigeration, thereby reducing energy consumption and storage/transport costs while maintaining protein stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of alkylglycosides and saccharide alkyl esters in protein formulations effectively reduces aggregation, increases stability, and decreases immunogenicity, leading to improved shelf-life and delivery conditions without the need for stringent cold-chain storage.
Implementation Method 1
at least one surfactant, wherein the surfactant is further comprised of at least one alkylglycoside and/or saccharide alkyl ester
Implementation Method 2
The concentrations of alkylglycoside found to be effective in this application must be at least somewhat higher than the critical micelle concentration
Data Source
AI summary
The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.